Nebido® publications portal (NPP)

Welcome to the Nebido® publications portal (NPP)

The purpose of the Nebido® publications portal (NPP) is to present testosterone related research, in an easily searchable and navigable interface, to health professionals who search for scientific information on hypogonadism, testosterone replacement therapy and testosterone related health issues.

CONTROLLED CLINICAL TRIAL
 | 
2003
Wittert GA
Chapman IM
Haren MT
Mackintosh S
Coates P
Morley JE
J Gerontol A Biol Sci Med Sci. 2003 Jul;58(7):618-25
Oral testosterone undecanoate (80 mg twice daily) in healthy men aged 60 years or older for 1 year increases lean body mass and decreases fat mass, with minimal side effects.
These beneficial effects on body composition may contribute to prevent development of age-related sarcopenia and frailty.
CONTROLLED CLINICAL TRIAL
 | 
2003
Storer TW
Magliano L
Woodhouse L
Lee ML
Dzekov C
Dzekov J
Casaburi R
Bhasin S
J Clin Endocrinol Metab. 2003 Apr;88(4):1478-85
Testosterone administration is associated with a dose-dependent increases in leg press strength and leg power.
Increases in leg press strength and leg power are directly correlated with total and free testosterone levels.
CONTROLLED CLINICAL TRIAL
 | 
2002
Ferrando AA
Sheffield-Moore M
Yeckel CW
Gilkison C
Jiang J
Achacosa A
Lieberman SA
Tipton K
Wolfe RR
Urban RJ
Am J Physiol Endocrinol Metab. 2002 Mar;282(3):E601-7
Testosterone administration to men >60 years with baseline testosterone levels of <17 nmol/l (480 ng/dl) for 6 months increases total and leg lean body mass, muscle volume, and leg and arm muscle strength. Increases in lean body mass resulted from an increase in muscle protein net balance, due to a decrease in muscle protein breakdown.
Testosterone administration increases expression of both androgen receptor and IGF-I protein in muscle. The increased androgen receptor expression may be temporary or required dose escalation in order to not return to baseline levels.
CONTROLLED CLINICAL TRIAL
 | 
2001
Kenny AM
Prestwood KM
Gruman CA
Marcello KM
Raisz LG
J Gerontol A Biol Sci Med Sci. 2001 May;56(5):M266-72
Testosterone replacement therapy with transdermal testosterone in men aged 65-87 years with low bioavailable testosterone levels <4.44 nmol/L prevents bone loss, decreases body fat, and increases lean body mass.
A modest increase in PSA levels were seen, but no change in signs or symptoms of prostate hyperplasia.
CONTROLLED CLINICAL TRIAL
 | 
2000
Wang C
Swerdloff RS
Iranmanesh A
Dobs A
Snyder PJ
Cunningham G
Matsumoto AM
Weber T
Berman N
Testosterone Gel Study Group
J Clin Endocrinol Metab. 2000 Aug;85(8):2839-53
Testosterone replacement therapy with transdermal gel reduces reduction fat mass and percent body fat, while improving sexual function and mood, and increased lean body mass and muscle strength. There were no significant changes in the lipid profile.
As anticipated, hematocrit and hemoglobin increases, but still within the normal range. The increase in mean serum prostate-specific antigen levels (within the normal range) was correlated with the increase in serum testosterone levels. Transdermal gel was better tolerated than patch, and in contrast to patch treatment, resulted in reduction fat mass and percent fat.
CONTROLLED CLINICAL TRIAL
 | 
2000
Snyder PJ
Peachey H
Berlin JA
Hannoush P
Haddad G
Dlewati A
Santanna J
Loh L
Lenrow DA
Holmes JH
Kapoor SC
Atkinson LE
Strom BL
J Clin Endocrinol Metab. 2000 Aug;85(8):2670-7
Testosterone replacement therapy for up to 3 years safely increases bone mineral density and fat-free mass, with no detrimental effects on lipids, hematocrit or prostate volume. This study shows that there is an initial elevation in safety parameters like hematocrit and prostate volume, from sub-normal to normal, after which they stabilize.
Improvements in self-reported sexual function and sense of energy occur relatively soon within the first 3 months of treatment.
CONTROLLED CLINICAL TRIAL
 | 
1995
Mårin P
Obes Res. 1995 Nov;3 Suppl 4:609S-612S
Treatment of middle-aged men with abdominal obesity with transdermal testosterone for 9 months decreased visceral fat mass (measured by CT-scan), increased insulin sensitivity (measured with the euglycemic glucose clamp), decrease in fasting blood glucose, plasma cholesterol and triglycerides as well as diastolic blood pressure. Treatment with DHT increased visceral mass was detected. No other changes were found in the DHT and P groups.
Testosterone therapy in abdominally obese men results in general metabolic and circulatory improvements. There were no detectable changes in prostate volume (measured by ultra-sound), prostate specific antigen concentration, genito-urinary history or urinary flow measurements in any of the groups.
CONTROLLED CLINICAL TRIAL
 | 
1994
Mårin P
Rosmond R
Bengtsson BA
Gustafsson C
Holm G
Björntorp P Obes Res
Obes Res. 1994 May;2(3):263-70
Visceral obesity in men is characterized by low testosterone (T) and insulin-like growth factor I (IGF-I) concentrations, the latter suggesting a relative growth hormone (GH) deficiency. Testosterone therapy in visceral obese men elevates IGF-I levels and improves blood glucose, chlolesterol and triglycerides and diastolic blood pressure.
It is suggested that IGF-I elevation with testosterone therapy might be due either to minor, non-detectable increases in GH secretion, or to direct effects of T on IGF-I concentrations. The mechanisms by which T-administration are leading to metabolic and anthropometric improvements, might be direct effects of T, with or without mediation via GH secretion.
  • PP-NEB-ALL-0347-1

Copyright © 2019,
Bayer AG

This website is intended to provide information to an international audience outside the USA and UK.

Page last modified Mon, 16/09/2019

Bayer logo